$2.59 Billion is the total value of Deep Track Capital, LP's 63 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| Exit | MINK THERAPEUTICS INC | $0 | – | -324,867 | -100.0% | -0.03% | – | |
| IMUX | Exit | IMMUNIC INC | $0 | – | -308,314 | -100.0% | -0.04% | – |
| ALLK | Exit | ALLAKOS INC | $0 | – | -228,277 | -100.0% | -0.05% | – |
| FGEN | Exit | FIBROGEN INCcall | $0 | – | -764,700 | -100.0% | -0.10% | – |
| Exit | MOONLAKE IMMUNOTHERAPEUTICSclass a ord | $0 | – | -108,450 | -100.0% | -0.26% | – | |
| ZNTL | Exit | ZENTALIS PHARMACEUTICALS INC | $0 | – | -300,300 | -100.0% | -0.39% | – |
| INZY | Exit | INOZYME PHARMA INC | $0 | – | -1,644,021 | -100.0% | -0.42% | – |
| ORTX | Exit | ORCHARD THERAPEUTICS PLCspon ads new | $0 | – | -2,041,670 | -100.0% | -0.49% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| JAZZ PHARMACEUTICALS PLC | 8 | Q3 2023 | 7.2% |
| TRAVERE THERAPEUTICS INC | 8 | Q3 2023 | 5.7% |
| IMMUNOVANT INC | 8 | Q3 2023 | 7.2% |
| BICYCLE THERAPEUTICS PLC | 8 | Q3 2023 | 5.2% |
| BEAM THERAPEUTICS INC | 8 | Q3 2023 | 3.9% |
| 4D MOLECULAR THERAPEUTICS IN | 8 | Q3 2023 | 2.9% |
| REPARE THERAPEUTICS INC | 8 | Q3 2023 | 3.1% |
| VIRIDIAN THERAPEUTICS INC | 8 | Q3 2023 | 2.2% |
| DYNE THERAPEUTICS INC | 8 | Q3 2023 | 2.2% |
| SILENCE THERAPEUTICS PLC | 8 | Q3 2023 | 1.6% |
View Deep Track Capital, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Orchard Therapeutics plc | March 20, 2023 | 19,125,150 | 10.0% |
| ARDELYX, INC.Sold out | February 14, 2023 | 0 | 0.0% |
| ASSEMBLY BIOSCIENCES, INC. | February 14, 2023 | 1,833,437 | 3.8% |
| Aurinia Pharmaceuticals Inc. | February 14, 2023 | 324,238 | 0.2% |
| CHINOOK THERAPEUTICS, INC. | February 14, 2023 | 3,000,000 | 4.7% |
| Forma Therapeutics Holdings, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Global Blood Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| HOOKIPA Pharma Inc. | February 14, 2023 | 1,240,369 | 2.4% |
| KalVista Pharmaceuticals, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Keros Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
View Deep Track Capital, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-26 |
| SC 13G | 2024-04-26 |
| SC 13G/A | 2024-04-22 |
| SC 13G | 2024-04-12 |
| SC 13G | 2024-04-05 |
| SC 13G | 2024-03-22 |
| SC 13G | 2024-03-22 |
| SC 13G | 2024-03-22 |
| SC 13G | 2024-03-15 |
| 3 | 2024-03-14 |
View Deep Track Capital, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.